The filing for a shelf registration by Kazia Therapeutics indicates that a stockholder may sell a significant number of ADS, which could increase the stock's supply in the market. This potential increase in supply might lead to downward pressure on the stock price in the short term, as the market absorbs the additional shares. However, the actual impact will depend on the demand for the shares and the timing of any sales.